At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 14 enrolled
Drug / intervention
AVP-923-45 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a, Double-blind, Randomized, Placebo-controlled, Crossover Study to Evaluate the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients.
In Brief
A Phase 2 clinical trial evaluating AVP-923-45 and Placebo for Dyskinesia and Parkinson's Disease. Completed, enrolled 14 participants across 3 sites in 2 countries.
Detailed Summary
To evaluate the efficacy, safety, and tolerability of AVP-923 capsules containing 45 mg dextromethorphan and 10 mg quinidine (AVP-923-45) compared to placebo for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDyskinesia, Parkinson's Disease
CountriesCanada, United States
CollaboratorsMichael J. Fox Foundation for Parkinson's Research
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 2013
Enrollment StartOct 2013
Primary CompletionFeb 2015
TodayJul 2026
First PostedJan 14, 2013
Enrollment StartOct 16, 2013
Primary CompletionFeb 5, 2015
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 13.5 years ago
Interventions
AVP-923-45drug
One capsule twice daily for 14 days
Placebodrug
One capsule twice daily for 14 days